Unknown

Dataset Information

0

Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival.


ABSTRACT: Trastuzumab targets the HER2 receptor on breast cancer cells to attenuate HER2-driven tumor growth. However, resistance to trastuzumab-based therapy remains a major clinical problem for women with HER2+ breast cancer. Breast cancer stem cells (BCSCs) are suggested to be responsible for drug resistance and tumor recurrence. Notch signaling has been shown to promote BCSC survival and self-renewal. Trastuzumab-resistant cells have increased Notch-1 expression. Notch signaling drives cell proliferation in vitro and is required for tumor recurrence in vivo. We demonstrate herein a mechanism by which Notch-1 is required for trastuzumab resistance by repressing PTEN expression to contribute to activation of ERK1/2 signaling. Furthermore, Notch-1-mediated inhibition of PTEN is necessary for BCSC survival in vitro and in vivo. Inhibition of MEK1/2-ERK1/2 signaling in trastuzumab-resistant breast cancer cells mimics effects of Notch-1 knockdown on bulk cell proliferation and BCSC survival. These findings suggest that Notch-1 contributes to trastuzumab resistance by repressing PTEN and this may lead to hyperactivation of ERK1/2 signaling. Furthermore, high Notch-1 and low PTEN mRNA expression may predict poorer overall survival in women with breast cancer. Notch-1 protein expression predicts poorer survival in women with HER2+ breast cancer. These results support a potential future clinical trial combining anti-Notch-1 and anti-MEK/ERK therapy for trastuzumab-resistant breast cancer.

SUBMITTER: Baker A 

PROVIDER: S-EPMC9115842 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival.

Baker Andrew A   Wyatt Debra D   Bocchetta Maurizio M   Li Jun J   Filipovic Aleksandra A   Green Andrew A   Peiffer Daniel S DS   Fuqua Suzanne S   Miele Lucio L   Albain Kathy S KS   Osipo Clodia C  

Oncogene 20180510 33


Trastuzumab targets the HER2 receptor on breast cancer cells to attenuate HER2-driven tumor growth. However, resistance to trastuzumab-based therapy remains a major clinical problem for women with HER2+ breast cancer. Breast cancer stem cells (BCSCs) are suggested to be responsible for drug resistance and tumor recurrence. Notch signaling has been shown to promote BCSC survival and self-renewal. Trastuzumab-resistant cells have increased Notch-1 expression. Notch signaling drives cell proliferat  ...[more]

Similar Datasets

| S-EPMC9855287 | biostudies-literature
| S-EPMC6463782 | biostudies-literature
| S-EPMC7011155 | biostudies-literature
| S-EPMC4245871 | biostudies-other
| S-EPMC10867587 | biostudies-literature
| S-EPMC4338147 | biostudies-literature
| S-EPMC3984319 | biostudies-literature
| S-EPMC6416795 | biostudies-literature
| S-EPMC6990915 | biostudies-literature
| S-EPMC5998300 | biostudies-literature